NO20061470L - Fremgangsmate for fremstilling av gamma-karboksylerte proteiner - Google Patents

Fremgangsmate for fremstilling av gamma-karboksylerte proteiner

Info

Publication number
NO20061470L
NO20061470L NO20061470A NO20061470A NO20061470L NO 20061470 L NO20061470 L NO 20061470L NO 20061470 A NO20061470 A NO 20061470A NO 20061470 A NO20061470 A NO 20061470A NO 20061470 L NO20061470 L NO 20061470L
Authority
NO
Norway
Prior art keywords
gamma
preparation
carboxylated
proteins
protein
Prior art date
Application number
NO20061470A
Other languages
English (en)
Other versions
NO339740B1 (no
Inventor
Ann Lovgren
Anders Thelin
Christel Fenge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29559260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061470(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20061470L publication Critical patent/NO20061470L/no
Publication of NO339740B1 publication Critical patent/NO339740B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter og verktøy for fremstilling av store mengder gamma-karboksylert protein ornfattende: (i) dyrkning av en celle tilpasset til å uttrykke et protein som krever gamma-karboksylering og (-glutamyl karboksylase i en ratio på minst 10:1, under betingelser egnet for ekspresjon av begge proteinene og (ii) isolering av gamma-karboksylert protein.
NO20061470A 2003-10-14 2006-03-31 Eukaryot vertscelle som omfatter minst en ekspresjonsvektor, nevnte vektor omfattende et nukleinsyremolekyl, metode for å produsere gamma-karboksylert protein samt metode for å produsere farmasøytisk preparat basert på samme NO339740B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324044.7A GB0324044D0 (en) 2003-10-14 2003-10-14 Protein
PCT/SE2004/001453 WO2005038019A1 (en) 2003-10-14 2004-10-12 Method for producing gamma-carboxylated proteins

Publications (2)

Publication Number Publication Date
NO20061470L true NO20061470L (no) 2006-05-12
NO339740B1 NO339740B1 (no) 2017-01-30

Family

ID=29559260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061470A NO339740B1 (no) 2003-10-14 2006-03-31 Eukaryot vertscelle som omfatter minst en ekspresjonsvektor, nevnte vektor omfattende et nukleinsyremolekyl, metode for å produsere gamma-karboksylert protein samt metode for å produsere farmasøytisk preparat basert på samme

Country Status (28)

Country Link
US (2) US7842477B2 (no)
EP (2) EP2292748B1 (no)
JP (1) JP4658946B2 (no)
KR (1) KR101201020B1 (no)
CN (2) CN1867669B (no)
AR (1) AR046180A1 (no)
AT (1) ATE491789T1 (no)
AU (2) AU2004281350B2 (no)
BR (1) BRPI0415277A (no)
CA (1) CA2541764C (no)
CO (1) CO5690657A2 (no)
DE (1) DE602004030603D1 (no)
DK (1) DK1678297T3 (no)
ES (2) ES2357603T3 (no)
GB (1) GB0324044D0 (no)
IL (2) IL174633A (no)
IS (1) IS8447A (no)
MX (1) MXPA06004060A (no)
MY (1) MY141859A (no)
NO (1) NO339740B1 (no)
NZ (2) NZ578306A (no)
PL (1) PL1678297T3 (no)
PT (1) PT1678297E (no)
RU (2) RU2372401C2 (no)
TW (1) TWI355419B (no)
UY (1) UY28558A1 (no)
WO (1) WO2005038019A1 (no)
ZA (1) ZA200603038B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380985B1 (en) * 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
AU2005329450A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active Vitamin K-dependent proteins
NZ561925A (en) 2005-04-13 2010-04-30 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
US20090137001A1 (en) * 2005-09-30 2009-05-28 Tatsufumi Onchi Process for preparing recombinant human thrombin with culture cell
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
EP1969127B8 (en) * 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
JP2009528843A (ja) * 2006-03-06 2009-08-13 ヒューマジーン・インコーポレイテッド 組換えヒトトロンビンおよびフィブリノゲンの調製法
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
CA2812888A1 (en) * 2010-10-06 2012-04-12 Medimmune Limited Factor ii and fibrinogen for treatment of haemostatic disorders
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
CN103814137A (zh) * 2011-09-06 2014-05-21 米迪缪尼有限公司 处理凝血因子的方法
RU2500816C1 (ru) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
JP5830486B2 (ja) 2013-03-29 2015-12-09 シスメックス株式会社 組換えバキュロウイルスおよびその利用
ES2758505T3 (es) * 2013-12-20 2020-05-05 Novartis Ag Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
CN109207462B (zh) * 2018-08-01 2021-05-11 深圳市新产业生物医学工程股份有限公司 异常凝血酶原及其制备方法和包含其的检测剂、试剂盒及应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043857A1 (de) 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
US4599308A (en) * 1981-10-06 1986-07-08 Hamer Dean H Protein from SV40 recombinants
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
WO1988003926A1 (en) 1986-11-17 1988-06-02 New England Medical Center Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
US6224864B1 (en) 1986-12-03 2001-05-01 Pharmacia & Upjohn Company Antibiotic 10381A, and process for the preparation of anitbiotics 10381B
WO1989012685A1 (en) 1987-05-18 1989-12-28 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
EP0540650A1 (en) 1990-07-23 1993-05-12 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
DE4430204A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
SI0796623T1 (en) 1996-03-20 2005-10-31 Baxter Aktiengesellschaft Pharmaceutical preparation for the treatment of blood coagulation disorders
ES2340008T3 (es) * 1997-02-14 2010-05-27 American Red Cross Expresion de factor ix humano activo en tejido mamario de animales transgenicos.
WO1999033983A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
AU6366100A (en) 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
US20020106381A1 (en) * 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
EP1325127B1 (en) * 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Method for the production of vitamin k-dependent proteins
JP4150814B2 (ja) 2001-07-06 2008-09-17 財団法人化学及血清療法研究所 遺伝子組換えエカリン及びその製造方法
CA2452768C (en) 2001-07-06 2011-06-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for preparing human thrombin by genetic engineering technique
ES2407134T3 (es) 2001-07-10 2013-06-11 The Chemo-Sero-Therapeutic Research Institute Composiciones hemostáticas farmacéuticamente estables
EP2380985B1 (en) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
ATE466074T1 (de) 2003-10-14 2010-05-15 Baxter Int Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
EP1676911B1 (en) 2003-10-24 2010-04-21 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Novel recombinant animal cells with high protein production, method of constructing the same and method of mass protein production using the same
JP2008523837A (ja) 2004-12-21 2008-07-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ガンマ―カルボキシル化に欠陥のある宿主系におけるガンマ―カルボキシル化ポリペプチドの発現
NZ561925A (en) 2005-04-13 2010-04-30 Astrazeneca Ab A host cell comprising a vector for production of proteins requiring gamma-carboxylation
EP1963506B1 (en) 2005-12-02 2010-10-27 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
EP1969127B8 (en) 2005-12-21 2017-12-13 Aptevo BioTherapeutics LLC Method of producing biologically active vitamin k dependent proteins by recombinant methods
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin

Also Published As

Publication number Publication date
IL226313A0 (en) 2013-06-27
CA2541764A1 (en) 2005-04-28
MXPA06004060A (es) 2006-06-28
CN1867669B (zh) 2011-10-19
NZ546584A (en) 2009-08-28
ATE491789T1 (de) 2011-01-15
ZA200603038B (en) 2007-09-26
PL1678297T3 (pl) 2011-11-30
JP2007508820A (ja) 2007-04-12
TWI355419B (en) 2012-01-01
US7842477B2 (en) 2010-11-30
JP4658946B2 (ja) 2011-03-23
US20110092429A1 (en) 2011-04-21
HK1155475A1 (en) 2012-05-18
EP2292748A1 (en) 2011-03-09
ES2357603T3 (es) 2011-04-28
IL174633A0 (en) 2006-08-20
MY141859A (en) 2010-07-16
US8697440B2 (en) 2014-04-15
AU2004281350A1 (en) 2005-04-28
GB0324044D0 (en) 2003-11-19
AR046180A1 (es) 2005-11-30
KR101201020B1 (ko) 2012-11-14
RU2006110147A (ru) 2007-11-20
RU2009123931A (ru) 2010-12-27
US20050164367A1 (en) 2005-07-28
NZ578306A (en) 2011-02-25
EP1678297B1 (en) 2010-12-15
CN102443548A (zh) 2012-05-09
CN1867669A (zh) 2006-11-22
DE602004030603D1 (de) 2011-01-27
CO5690657A2 (es) 2006-10-31
ES2532470T3 (es) 2015-03-27
BRPI0415277A (pt) 2006-12-19
EP2292748B1 (en) 2014-12-17
DK1678297T3 (da) 2011-03-14
KR20060123152A (ko) 2006-12-01
TW200523365A (en) 2005-07-16
CA2541764C (en) 2015-03-31
AU2004281350B2 (en) 2008-05-15
RU2372401C2 (ru) 2009-11-10
IS8447A (is) 2006-05-10
IL174633A (en) 2013-06-27
WO2005038019A1 (en) 2005-04-28
EP1678297A1 (en) 2006-07-12
NO339740B1 (no) 2017-01-30
UY28558A1 (es) 2005-05-31
PT1678297E (pt) 2011-03-15
AU2008205445A1 (en) 2008-09-04
CN102443548B (zh) 2014-03-12

Similar Documents

Publication Publication Date Title
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
EP3486314A3 (en) Placental stem cell populations
SG149061A1 (en) Definitive endoderm
ATE313620T1 (de) Wirtszellen und methoden für die produktion von proteinen
DK1791860T3 (da) Oprensningsfremgangsmåde for bakterielt cytolysin
DE60228439D1 (de) Verbesserte isoprenoid herstellung
WO2002031134A3 (en) Novel serine protease genes related to dppiv
NO20081622L (no) Fremgangsmater for produksjon av proteiner ved anvendelse av anti-senescence forbindelser
DK1546316T3 (da) Mutant E. Coli-AppA-fytaseenzymer og naturlige varianter deraf, nukleinsyrer, der koder for sådanne fytaseenzymer, vektorer og værtsceller, som inkorporerer disse og fremgangsmåder til at fremstille og anvende disse
NO20072719L (no) Serumfritt cellekulturmedium for pattedyrceller
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
WO2006116949A8 (en) A new bacillus subtilis strain and its use in preparing medicine for treating thrombosis
ATE365203T1 (de) Hefe-extraktlösung, ihre herstellung und verwendung zur zellfreien proteinsynthese
NO20051841L (no) Fremgangsmate for a oke produksjon av blodplater og hematopoietiske stamceller.
NO20075911L (no) Genetisk modifisert mikroorganisme og fremgangsmate for fremstilling av makrolidforbindelser ved anvendelse av mikroorganismen
ATE546521T1 (de) Sesquiterpene synthasen und verwerdungsmethoden
WO2004011637A3 (en) Modified adamts4 molecules and method of use thereof
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
IL180531A0 (en) Novel sequence for improving expression of nucleic acid
ATE415470T1 (de) Herstellungsverfahren für iturin a und dessen homologe
WO2005054447A3 (en) Müller stem cells
WO2005046581A3 (en) P18 in stem cell manipulations
AR034778A1 (es) Una nueva isomerasa termoestable y su uso, en particular para producir tagatosa
WO2002010344A3 (en) Synchronised arabidopsis cell suspensions and uses thereof
AU2003242533A1 (en) Glutamine-free medium

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees